# Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

> **NCT02160626** · PHASE2 · COMPLETED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 172 (actual)

## Conditions studied

- Seborrheic Keratosis

## Interventions

- **DRUG:** A-101 Vehicle
- **DRUG:** A-101 (40) Topical Solution
- **DRUG:** A-101 (32.5) Topical Solution

## Key facts

- **NCT ID:** NCT02160626
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2019-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02160626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02160626, "Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02160626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*